Vergelijking
Ganirelix vs. Leuprorelin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
123246-29-7
53714-56-0
Molecuulmassa
1570.3 g/mol
1209.4 g/mol
Halfwaardetijd
geen gegevens
3 h
Sequentie
geen gegevens
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtWerkingsmechanisme
Ganirelix
Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
1
4
waarvan bij mensen
1
4
Geregistreerde effecten
2
4
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
3
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Ganirelix and Leuprorelin?
- Ganirelix is classified as "Onderzoek (overig)", while Leuprorelin is classified as "Onderzoek (overig)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ganirelix or Leuprorelin?
- The highest available evidence level is "Humane RCT" for Ganirelix and "Humane RCT" for Leuprorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ganirelix and Leuprorelin in Germany and the United States?
- Duitsland: Ganirelix — Op recept, Leuprorelin — Op recept. Verenigde Staten: Ganirelix — Op recept, Leuprorelin — Op recept. These are factual summaries with source and review date on the individual pages.